Norman D. Schwartz - 26 Aug 2022 Form 4 Insider Report for BIO-RAD LABORATORIES, INC. (BIO)

Role
Chairman, President, and CEO, Director, 10%+ Owner
Signature
/s/ Norman Schwartz
Issuer symbol
BIO
Transactions as of
26 Aug 2022
Net transactions value
-$7,550,095
Form type
4
Filing time
29 Aug 2022, 19:45:05 UTC
Previous filing
23 Nov 2021
Next filing
06 Sep 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BIO Bio-Rad B Common Stock Options Exercise $4,212,310 +39,250 +12% $107.32 355,396 26 Aug 2022 Direct
transaction BIO Bio-Rad B Common Stock Tax liability $11,762,405 -23,749 -6.7% $495.28 331,647 26 Aug 2022 Direct
holding BIO Bio-Rad B Common Stock 12,858 26 Aug 2022 By Spouse F1
holding BIO Bio-Rad B Common Stock 4,060,054 26 Aug 2022 By Blue Raven Partners, L.P. F2
holding BIO Bio-Rad A Common Stock 423,670 26 Aug 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BIO Non-Qualified Stock Option (right to buy) Options Exercise $0 -39,250 -100% $0.000000* 0 26 Aug 2022 Bio-Rad B Common Stock 39,250 $107.32 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reporting person disclaims beneficial ownership of these shares.
F2 The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
F3 The option, representing a right to purchase a total of 39,250 shares, became exercisable in five equal annual installments beginning on September 12, 2013, which was the first anniversary of the date on which the option was granted.